Last Update Time:
17-Mar-2025 16:00:00
ISIN:
INE083D01012
Sector:
Healthcare
Symbol:
BALPHARMA
Bal Pharma Limited
₹80.50
₹-1.70
(-2.07%)
▼
Prev. Close
₹82.20
Open
₹84.50
Close
₹81.36
Range
₹76.48 - ₹84.53
High
₹84.50
Low
₹80.50
Ind. Close
₹0.00
VWAP
₹81.83
The current stock price of Bal Pharma Limited is ₹80.50, with a target price range between ₹76.48 and ₹84.53. The stock has experienced a price change of ₹-1.70 (-2.07%), reflecting recent market volatility.
Today's opening price was ₹84.50, while the previous close stood at ₹82.20.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Bal Pharma Limited Price Chart
Bal Pharma Limited Pre Open Market Overview: 17-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 84.5
- Previous Close Price: 82.2
- Change: 2.30%
- Total Traded Volume: 25
- Total Buy Quantity: 3,513
- Total Sell Quantity: 2,502
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 81.00 | 1.00 | 0.00 |
| 81.01 | 30.00 | 0.00 |
| 81.05 | 200.00 | 0.00 |
| 82.95 | 25.00 | 0.00 |
| 83.00 | 110.00 | 0.00 |
| 84.50 | 0.00 | 587.00 |
| 84.65 | 0.00 | 54.00 |
| 84.90 | 0.00 | 100.00 |
| 85.00 | 0.00 | 15.00 |
| 89.00 | 0.00 | 250.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 3513
Total Sell Quantity: 2502
Shareholding Patterns of Bal Pharma Limited
Key Trade Statistics of Bal Pharma Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.23 |
| Traded Value (₹ Cr.) | 0.19 |
| Total Market Cap (₹ Cr.) | 128.16 |
| Free Float Market Cap (₹ Cr.) | 61.98 |
| Impact cost | 1.95 |
| Quantity Traded | 22,807.00 |
| Deliverable Quantity | 15,722.00 |
| % of Quantity to Traded | 68.93 |
| Security VaR | 19.47 |
| Index VaR | N/A |
| VaR Margin | 21.5 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 25 |
| Face Value | 10 |
Key Price Statistics of Bal Pharma Limited
The 52-week high for Bal Pharma Limited was ₹157.98, recorded on 28-Aug-2024. On the other hand, the 52-week low stands at ₹78.06, with the lowest value recorded on 04-Mar-2025.
The upper band for trading is ₹98.64, and the lower band is ₹65.76. The price band is 20%.
The stock's daily volatility stands at 2.97, while the annualized volatility is 56.74. The tick size for trading is ₹0.01.
| Price Information | Details |
|---|---|
| 52 Week High (28-Aug-2024) | 157.98 |
| 52 Week Low (04-Mar-2025) | 78.06 |
| Upper Band | 98.64 |
| Lower Band | 65.76 |
| Price Band (%) | 20 |
| Daily Volatility | 2.97 |
| Annualised Volatility | 56.74 |
| Tick Size | 0.01 |
Key Securities Statistics of Bal Pharma Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 08-May-2006 |
| Adjusted P/E | 17.8 |
| Symbol P/E | 17.8 |
| Index | NA |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Bal Pharma Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Bal Pharma Limited
| Subject | Date |
|---|---|
| Updates | 24-Feb-2025 |
| Copy of Newspaper Publication | 17-Feb-2025 |
| Integrated Filing- Financial | 14-Feb-2025 |
| Outcome of Board Meeting | 13-Feb-2025 |
| Financial Result Updates | 13-Feb-2025 |
| Board Meeting Intimation | 23-Jan-2025 |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 06-Jan-2025 |
| Structural Digital Database | 03-Jan-2025 |
Corporate Actions of Bal Pharma Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 10 | Annual General Me0etingdividend - Rs 1.2 Per Share | 17-Sep-2024 |
| 10 | Annual General Meeting/Dividend - Re 1 Per Share | 18-Sep-2023 |
| 10 | Annual General Meetingdividend - Re 1 Per Share | 13-Sep-2022 |
| 10 | Annual General Meeting/Dividend - Re 1 Per Share | 16-Sep-2021 |
| 10 | Annual General Meeting | 17-Sep-2020 |
| 10 | Annual General Meeting/Dividend - Re 1 Per Share | 17-Sep-2019 |
| 10 | Annual General Meeting/Dividend Re 1 Per Share | 14-Sep-2018 |
| 10 | Annual General Meeting/Dividend - Re 1/- Per Share | 14-Sep-2017 |
| 10 | Annual General Meeting/Dividend Re 1/- Per Share | 15-Sep-2016 |
| 10 | Annual General Meeting/ Dividend - Re 1/- Per Share | 15-Sep-2015 |
| 10 | Annual General Meeting / Dividend - Re 1/- Per Share | 12-Sep-2014 |
| 10 | Annual General Meeting / Dividend - Re 0.75/- Per Share | 12-Sep-2013 |
| 10 | Annual General Meeting | 17-Sep-2012 |
| 10 | Annual General Meeting | 19-Sep-2011 |
| 10 | Annual General Meeting | 23-Sep-2010 |
| 10 | Dividend-Re.0.75 Pr Share | 17-Sep-2009 |
| 10 | Agm/Dividend - 10% | 09-Sep-2008 |
| 10 | Agm/Dividend-7.5% | 07-Sep-2007 |
| 10 | Agm/Dividend-7.5% | 07-Sep-2006 |
Board Meetings of Bal Pharma Limited
Financial Results of Bal Pharma Limited
Company Directory of Bal Pharma Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.balpharma.com | Head Office/ Corporate Office | 5th floor, Lakshminarayan Complex, 10/1, Palace Road, | BANGALORE |
| www.balpharma.com | Registered Office | 21&22, Bommasandra Industrial Area, Anekal Taluk, | BANGALORE |
| www.balpharma.com | Transfer Agent | TSR Darashaw Ltd. 6-10 Haji Moosa Patrawala Industrial Estate,20,Dr.E Moses Road, Mahalaxmi | MUMBAI |
Insider Trading of Bal Pharma Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | SHAILESH SIROYA | 37500000 | Buy |
| 7(2) | MICRO LABS LIMITED | 36980069 | Buy |
| 7(2) | MICRO LABS LIMITED | 300900 | Buy |
| 7(2) | SHAILESH SIROYA | 32500000 | Buy |
| 7(2) | DILIP SURANA (HUF) | 0 | Buy |
| 7(2) | SHRENIK D SIROYA | 0 | Buy |
| 7(2) | JIVI DHEERAJMAL SIROYA | 0 | Buy |
| 7(2) | ANITA CHANDRAPRAKASH SIROYA | 0 | Buy |
| 7(2) | CHANDRAPRAKASH DHEERAJMAL SIROYA | 0 | Buy |
| 7(2) | MONIKA SURANA | 0 | Buy |
| 7(2) | ARCHANA SURANA | 0 | Buy |
| 7(2) | DILIP SURANA | 0 | Buy |
| 7(2) | MICRO LABS LIMITED | 0 | Buy |
| 7(2) | ANAND SURANA | 0 | Buy |
| 7(2) | SHAILESH D SIROYA | 0 | Buy |
| 7(2) | ANITA SIROYA | 0 | Buy |
| 7(2) | SUBBARAO PRASANNA | 0 | Buy |
| 7(2) | SHAILESH D SIROYA | 27000000 | Sell |
| 7(2) | SHREYA MARDIA | 27000000 | Buy |
| 7(2) | SHRENIK D SIROYA | 33000000 | Sell |
Annual Reports of Bal Pharma Limited
Investor Complaints of Bal Pharma Limited
Event Calendar of Bal Pharma Limited
| Purpose | Details |
|---|---|
| Financial Results | Among other things, the main purpose of the meeting is to consider, and take on record, the Unaudited Financial Results for the first quarter, ended on, June 30, 2010 and Audited Financial Results for the year ended on March 31, 2010. |
| Results/Others | Among other things, the main purpose of the meeting is to consider, and take on record, the Unaudited Financial Results for the 2nd quarter, ended on, September 30, 2010. |
| Financial Results | To consider and take on record, the Audited Financial Results of the Company for the entire financial year ended March 31, 2011, Unaudited Financial Results (UFR) for the first quarter ended June 30, 2011 and to discuss the AGM related matters. |
| Results/Others | Inter alia will transact the following business : (1) Take on record and approve the Un-Audited financial results of the Company for the quarter ended June 30, 2012; (2)Take on record and approve the Audited financial results of the company for the financial year ended March 31, 2012; (3) Propose issue and allotment of warrants on preferential basis to the promoters and to strategic investors, subject to the approval of the members; (4) Approve the audited accounts of the Company for the F.Y ended March 31, 2012 along with the notice for AGM, Directors Report and Corporate Governance Report; (5) Decide on the book closure date and AGM date. |
| Results | Inter alia will be taking on record and approve the Un-Audited Financial Results of the Company for the quarter ended December 31, 2012. |
| Results/Dividend | Inter alia, will be transacting the following: (1) To consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2013 (2) Recommendation of Dividend, if any (3) Approve the audited accounts of the Company for the FY ended March 31, 2013 along with the notice of A.G.M., Director s Report and Corporate Governance Report (4) To decide on the book closure and A G M date. |
| Results | Inter-alia, to take on record and approve the Un-Audited financial results of the Company for the quarter ended June 30, 2013. |
| Results | The Board of Directors inter alia will be taking on record and approve the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2013. |
| Results/Others | Inter alia will be transacting the following business: 1.Take on record and approve the Un-Audited financial results of the Company for the quarter ended 31.12.2013. 2. To issue and allot equity shares pursuant to the conversion of warrants. |
| Results/Dividend | Inter alia will be transacting the following business, 1. Consideration of the Audited Financial Results of the Company for the IVth quarter and financial year ended 31.03.2014. 2. Appropriation of profits including recommendation of Dividend, if any. 3. Consideration of various subjects relating to Annual General Meeting. 4. Book closure and Convening of A.G.M . 5. Any other business with the permission of the Chairman. |
| Results/Others | for considering inter alia Un-Audited Financial results for the quarter ended 30.06.2014, & also proposal for preferential issue of securities will also be taken up for consideration by the Board at the said meeting. (purpose revised) |
| Results | inter alia will be taking on record and approve the Un-Audited financial results of the Company for the quarter ended June 30, 2014. |
| Results | Inter alia will be taking on record and approve the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2014. |
| Results | inter considering taking on record and approval of Un-Audited financial results of the Company for the quarter ended December 31, 2014. |
| Results/Dividend | The Board Inter alia will be transacting the following business, 1. Consideration of the Audited Financial Results of the Company for the 4th quarter and financial year ended on March 31, 2015. 2. Appropriation of profits including recommendation of Dividend, if any. |
| Results/Others | Inter alia will be transacting the following business, 1. To take on record and approve the Un-audited financial results of the Company for the 1st quarter ended June 30, 2015. 2. Fixing of Book closure and Annual General Meeting dates. 3. Other AGM related matters. |
| Results | inter alia will be considering taking on record and approval of Un-audited financial results of the Company for the quarter and half year ended September 30, 2015. |
| Results | inter alia will be taking on record and approve the unaudited financial results of the Company for the quarter ended December 31, 2015. |
| Results/Dividend | Inter alia will be transacting the following business,1. To take on record and approve the audited financial results of the Company for the financial year ended March 31, 2016.2. Appropriation of profits including recommendation of dividend if any, for the F.Y 2015.16.3. To consider various other A.G.M related aspects. |
| Results/Others | Sub : The Board of Directors inter alia will be transacting the following business. (1.) To take on record and approve the Un-audited financial results of the Company for the quarter ended June 30, 2016. (2).To approve the AGM Notice , Directors Report and Corporate Governance reports of the Company for the financial year ended March 31, 2016. (3). To decided on the Book closure dates for Financial Year 2015-16. 4. To consider other AGM related matters. 5. To consider certain key business propositions. |
| Results | Inter alia take on record and approve the Un-Audited financial results of the Company for the quarter and half year ended September 30, 2016. |
| Results | To inter alia take on record and approve the Un-Audited financial results of the Company for the quarter ended December 31, 2016. Further, pursuant to Prohibition of Insider Trading Regulations,2015 of SEBI and as per the provisions of Code of Conduct of the Company, the trading window on the designated employees of the Company and their immediate relatives shall remain closed from January 25, 2017 up to February 08, 2017. . |
| Results | Inter alia, Considering approval of audited stand alone and consolidated financial results of the Company for the financial year 2016.17. Further, pursuant to Prohibition of Insider Trading Regulations,2015 of SEBI and as per the provisions of Code of Conduct of the Company, the trading window on the designated employees of the Company and their immediate relatives will remain closed from 12.05.2017 up to 31.05.2017. |
| Results/Dividend | The Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on May 30, 2017 Inter alia, Considering approval of audited stand alone and consolidated financial results of the Company for the financial year 2016. The Company has now informed the Exchange that the Board inter alia will also be considering recommendation of Dividend for the financial year 2016.17,(Purpose Revised). |
| Others | inter alia will be transacting the following business. 1.To approve the 30th Annual General Meeting Notice (AGM), Directors Report and Corporate Governance reports of the Company, for the financial year ended March 31, 2017. 2. To decided on the Book closure dates. 3. To consider other AGM related matters　 |
| Results | Inter alia will be considering approval of Ind-AS compliant, un-audited stand alone and consolidated financial results of the Company for the quarter ended June 30, 2017. |
| Results | Inter alia will be considering approval of un audited stand alone and consolidated financial results of the Company for the quarter and half year ended September 30, 2017. |
| Results | The Board of Directors inter alia will be considering approval of un audited stand alone and consolidated financial results of the Company for the quarter ended December 31, 2017. |
| Financial Results/Dividend | inter alia will be considering. 1) Approval of Audited Stand Alone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2018. 2) Appropriation of profits including recommendation of dividend if any for the financial year 2017-18 |
| Financial Results/Other business matters | To Inter alia consider the following, a) Approval of the Un-audited financial results of the Company for the Quarter ended June 30, 2018. b) To decide on the Book closure and t Annual General Meeting dates. c) Other Annual General Meeting related matters. |
| Financial Results | Inter alia will be considering approval of Un-audited stand alone and consolidated financial results of the Company for the quarter and half year ended September 30, 2018. |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2019 and Closure of Trading Window. |
| Financial Results/Dividend | BALPHARMA : 30-May-2019 : The Company has informed the Exchange that a Board meeting to be held on May 29, 2019 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 30, 2019, To consider and approve the financial results for the period ended March 31, 2019 and dividend |
| Financial Results | To inter alia consider and approve the financial results for the period ended Jun 30, 2019. |
| Financial Results | BALPHARMA : 13-Aug-2019 : The Company has informed the Exchange that a Board meeting to be held on August 08, 2019 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on August 13, 2019, To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results/Other business matters | BALPHARMA : 13-Aug-2019 : The Company has informed the Exchange that a Board meeting to be held on August 08, 2019 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on August 13, 2019, To consider and approve the financial results for the period ended Jun 30, 2019 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2020 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2020 and other business propositions including fundraising options. |
| Other business matters | To consider other business matters , 1. Allotment of warrants on preferential basis. 2. Shift its focus from non core businesses like veterinary formulations . |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2020 and other business matters. |
| Other business matters | To consider allotment of equity shares on conversion of warrants. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2021 and dividend |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2021 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2021 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Other business matters | Bal Pharma Limited has informed the Exchange about Board Meeting to be held on 09-Mar-2022 to consider approval of scheme of amalgamation between Bal Pharma Ltd and its wholly owned subsidiary i.e Golden Drugs Pvt Ltd. |
| Other business matters | Notice is hereby given that the meeting of Board of Directors of the Company is scheduled to be held on 13.04.2022 i.e on Wednesday to inter alia consider allotment of equity shares to the beneficiaries who have exercised the conversion option on the warrants allotted to them on preferential basis. |
| Financial results | Bal Pharma Limited has informed the Exchange about Board Meeting to be held on 11-Aug-2022 to consider financial statements for the period ended June 2022 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2023, dividend and other business matters |
| Financial Results/Other business matters | 1.To consider and approve the Un-audited financial results (Standalone and Consolidated) for the period ended Jun 30, 2023 .2. To Convene 36th Annual General Meeting of the Company.3. To decide on the Book Closure dates.4. Other AGM related matters. |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2023 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2023 and to consider investing additional capital in expanding its manufacturing presence , through a green field project. |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2024, dividend and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2024 and other business matters |
| Other business matters | 1.Allotment of Equity Shares to the employees of the Company upon conversion of stock options vested on them.2. To consider expanding its manufacturing presence to meet the growing demand for Active Pharma Ingredients ( API's)3.Any other matter incidental to the business operations and ensuing Annual General Meeting of the Company. |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2024 and other business matters |
| Financial Results/Fund Raising | To consider and approve the financial results for the period ended December 31, 2024 and Fund Raising |
Share Transfers of Bal Pharma Limited
Voting Results of Bal Pharma Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 25-SEP-2024 | AGM | To receive, consider and adopt the audited standalone and consolidated financial results of the Commpany for the financial year ended 31.03.2024 togather with reports of the Board and Auditors |
| 25-SEP-2024 | AGM | To ratify the remuneration payable to the Cost Auditors for the financial year 2024-25 |
| 25-SEP-2024 | AGM | Reclassification of the promoter group |
| 25-SEP-2024 | AGM | To re-appoint Mr.Shailesh Siroya ( DIN # 00048109) as Managing Director of the Company and to fix his remuneration. |
| 25-SEP-2024 | AGM | To Re-Appoint Mr.Himesh Virupakshya ( DIN # 08554422) as Wole Time Director of the Company and to fix his remuneration. |
| 25-SEP-2024 | AGM | To appoint Director in place of Mr.Kotian Chittanand Damodar who is retiring by rotation and being eligible , offerrs himself for reappointment. |
| 25-SEP-2024 | AGM | To declare dividned of Rs.1.20 per equity share of Rs.10 each i.e 12% |
| 21-DEC-2023 | Court Convened Meeting | Approval of scheme of amalgamation between Golden Drugs Private Ltd ( Transferer Company ) with its holding Company i.e Bal Pharma Limited ( Transferee Company ) |
| 25-SEP-2023 | AGM | To receive , consider and adopt the audited standalone and consolidated finacial statements of the Company for the fiancial year ended 31st March,2023 |
| 25-SEP-2023 | AGM | To ratify the remuneration payable to the cost auditor |
| 25-SEP-2023 | AGM | To renew contract with Desa Marketing International |
| 25-SEP-2023 | AGM | To appoint Mr.Kotian Chittanand Damodar (din # 09613054) who was retiring by rotation and being eligible opted for reappointment. |
| 25-SEP-2023 | AGM | To declare a dividned of Re.1/- per equity share of Rs.10/- each. |
| 21-AUG-2023 | Postal Ballot | Reappointment of Ms.Nicola Neeladri (DIN # 01997936) as independent Director of the Company for second term of 5 years |
| 14-DEC-2022 | EGM | To seek the consent of memebrs for filing application under Section 230(1) of Companies Act,2013 with NCLT in connection with proposed merger of Wholly Owned Subsidiary i.e Golden Drugs Pvt Ltd (Transferer Company ) with Bal Pharma Ltd ( Transferee Commpany). |
| 19-SEP-2022 | AGM | To approve the Audited financial Statements of the Company for the F.Y ended 31.03.2022 to-gather with reports of the board and auditors. |
| 19-SEP-2022 | AGM | To adopt a new set of Memorandum of Association of the Company |
| 19-SEP-2022 | AGM | To appoint SSJNB & CO as statutory Auditors of the Company. |
| 19-SEP-2022 | AGM | To reappoint Mr.Himesh.V ( DIN # 08554422) who was retiring by rotation and being eligible offered him for reappointment. |
| 19-SEP-2022 | AGM | To declare dividned of Re.1 per equity share of Rs.10/- each. |
FAQs on Bal Pharma Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.